Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in IDH2-mutated Advanced Solid Tumors and AITL
NCT02273739Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in solid tumor, glioma, angioimmunoblastic T-cell lymphoma (AITL) and 2 more, sponsored by Celgene Corporation. Primary endpoints: Treatment-emergent Adverse Events, Dose-limiting Toxicities and 1 more. Started Dec 2014; status: completed.
02
Drugs
enasidenib
03
Conditions
solid tumorgliomaangioimmunoblastic T-cell lymphoma (AITL)intrahepatic cholangiocarcinoma (ICC)chondrosarcoma
Beyond the preview
Go deeper on NCT02273739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273739.